Y-mAbs Therapeutics (YMAB) PT Lowered to $11 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts YMAB Hot Sheet
Price: $8.61 --0%
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
H.C. Wainwright analyst Robert Burns lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $11.00 (from $19.00) while maintaining a Buy rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Biogen (BIIB) PT Raised to $275 at Freedom Broker
- Kymera Therapeutics (KYMR) PT Raised to $132 at Brookline Capital Markets
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
